We are live on ! Find out more
ELV icon

Elevance Health

1,030 hedge funds and large institutions have $64.3B invested in Elevance Health in 2019 Q2 according to their latest regulatory filings, with 98 funds opening new positions, 401 increasing their positions, 378 reducing their positions, and 129 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more repeat investments, than reductions

Existing positions increased: 401 | Existing positions reduced: 378

5% more call options, than puts

Call options by funds: $595M | Put options by funds: $568M

0.56% more ownership

Funds ownership: 88.33%88.9% (+0.56%)

1% less capital invested

Capital invested by funds: $65B → $64.3B (-$732M)

4% less funds holding

Funds holding: 1,0741,030 (-44)

20% less funds holding in top 10

Funds holding in top 10: 4536 (-9)

24% less first-time investments, than exits

New positions opened: 98 | Existing positions closed: 129

Holders
1,030
Holders Change
-44
Holders Change %
-4.1%
% of All Funds
22.37%
Holding in Top 10
36
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-20%
% of All Funds
0.78%
New
98
Increased
401
Reduced
378
Closed
129
Calls
$595M
Puts
$568M
Net Calls
+$27M
Net Calls Change
-$36.1M
Name Holding Trade Value Shares
Change
Change in
Stake
JFGIW
1026
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$1K
MWM
1027
Meridian Wealth Management
Kentucky
$584 +$56.5K +207 New
SQA
1028
Simon Quick Advisors
New Jersey
$564 +$546 +2 New
Acadian Asset Management
1029
Acadian Asset Management
Massachusetts
-$230M -801,569 Closed
MC
1030
Maverick Capital
Texas
-$208M -724,153 Closed
ECU
1031
Egerton Capital (UK)
United Kingdom
-$199M -694,185 Closed
Millennium Management
1032
Millennium Management
New York
-$169M -618,760 Closed
Point72 Asset Management
1033
Point72 Asset Management
Connecticut
-$173M -602,597 Closed
SCM
1034
Suvretta Capital Management
New York
-$81.3M -283,200 Closed
Renaissance Technologies
1035
Renaissance Technologies
New York
-$79.2M -275,973 Closed
PI
1036
PGGM Investments
Netherlands
-$57.3M -199,641 Closed
N
1037
Natixis
France
-$51.4M -182,052 Closed
MMH
1038
Menora Mivtachim Holdings
Israel
-$43.1M -150,360 Closed
Royal London Asset Management
1039
Royal London Asset Management
United Kingdom
-$42.1M -146,713 Closed
Capital Fund Management (CFM)
1040
Capital Fund Management (CFM)
France
-$21.3M -77,810 Closed
Two Sigma Advisers
1041
Two Sigma Advisers
New York
-$19.1M -66,697 Closed
CCP
1042
Clough Capital Partners
Massachusetts
-$19.1M -66,458 Closed
CHP
1043
Castle Hook Partners
New York
-$18.6M -64,924 Closed
QC
1044
Quadrature Capital
United Kingdom
-$14.9M -51,971 Closed
EGM
1045
Engineers Gate Manager
New York
-$14.7M -51,302 Closed
MGM
1046
Miura Global Management
New York
-$14.3M -50,000 Closed
TEC
1047
Tiger Eye Capital
Tennessee
-$13.4M -46,719 Closed
QIM
1048
Quantitative Investment Management
Virginia
-$12.7M -44,200 Closed
QT
1049
Quantbot Technologies
New York
-$10.2M -35,691 Closed
AIM
1050
Assured Investment Management
New York
-$6.41M -22,347 Closed

ELV Hedge Fund Activity: Q2 2019 in Review

1,030 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Elevance Health (ELV) for Q2 2019, worth a combined $64.3B — down 1.1% from $65B a quarter earlier.

Sellers outnumbered buyers: 129 funds closed out of ELV and 98 opened new positions — a net loss of 31 holders — while 378 trimmed existing stakes and 401 added.

The largest buyer was TCI Fund Management, opening a new position worth an estimated $823M. The largest seller was T. Rowe Price Associates, cutting an estimated $636M.

  • 1,030 institutional investors held Elevance Health (ELV) as of Q2 2019, down from 1,074 in Q1 2019.
  • Funds reported $64.3B of Elevance Health stock for Q2 2019, down 1.1% quarter-over-quarter.
  • 98 funds opened new Elevance Health positions in Q2 2019 and 129 closed out, a net change of -31 holders.
  • The largest Elevance Health buyer in Q2 2019 was TCI Fund Management, an estimated $823M added.
  • The largest Elevance Health seller in Q2 2019 was T. Rowe Price Associates, an estimated $636M sold.

Based on aggregated 13F filings for Q2 2019.